Molecules (Basel, Switzerland), 2021-04, Vol.26 (8), p.2204
2021
Details
- Autor(en) / Beteiligte
- Titel
- Resveratrol Enhances Inhibition Effects of Cisplatin on Cell Migration and Invasion and Tumor Growth in Breast Cancer MDA-MB-231 Cell Models In Vivo and In Vitro
- Ist Teil von
- Molecules (Basel, Switzerland), 2021-04, Vol.26 (8), p.2204
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Triple-negative breast cancer (TNBC) is a refractory type of breast cancer that does not yet have clinically effective drugs. The aim of this study is to investigate the synergistic effects and mechanisms of resveratrol combined with cisplatin on human breast cancer MDA-MB-231 (MDA231) cell viability, migration, and invasion in vivo and in vitro. In vitro, MTS assays showed that resveratrol combined with cisplatin inhibits cell viability as a concentration-dependent manner, and produced synergistic effects (CI < 1). Transwell assay showed that the combined treatment inhibits TGF-β1-induced cell migration and invasion. Immunofluorescence assays confirmed that resveratrol upregulated E-cadherin expression and downregulated vimentin expression. Western blot assay demonstrated that resveratrol combined with cisplatin significantly reduced the expression of fibronectin, vimentin, P-AKT, P-PI3K, P-JNK, P-ERK, Sma2, and Smad3 induced by TGF-β1 ( < 0.05), and increased the expression of E-cadherin ( < 0.05), respectively. In vivo, resveratrol enhanced tumor growth inhibition and reduced body weight loss and kidney function impairment by cisplatin in MDA231 xenografts, and significantly reduced the expressions of P-AKT, P-PI3K, Smad2, Smad3, P-JNK, P-ERK, and NF-κB in tumor tissues ( < 0.05). These results indicated that resveratrol combined with cisplatin inhibits the viability of breast cancer MDA231 cells synergistically, and inhibits MDA231 cells invasion and migration through Epithelial-mesenchymal transition (EMT) approach, and resveratrol enhanced anti-tumor effect and reduced side of cisplatin in MDA231 xenografts. The mechanism may be involved in the regulations of PI3K/AKT, JNK, ERK and NF-κB expressions.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1420-3049eISSN: 1420-3049DOI: 10.3390/molecules26082204Titel-ID: cdi_doaj_primary_oai_doaj_org_article_6d131aaed45e4f5ab324a125a9b61224
- Format
- –
- Schlagworte
- 1-Phosphatidylinositol 3-kinase, AKT protein, Animals, Assaying, Biomarkers, Tumor - metabolism, Body weight, Body weight loss, Breast cancer, Cancer therapies, Cell adhesion & migration, Cell culture, Cell growth, Cell Line, Tumor, Cell Movement - drug effects, Cell Proliferation - drug effects, Cell Survival - drug effects, Cell viability, Chemotherapy, Cisplatin, Cisplatin - pharmacology, Combined treatment, DNA repair, Drug dosages, Drug Synergism, E-cadherin, Epidermal growth factor, Epithelial-Mesenchymal Transition - drug effects, epithelial–mesenchymal transition, Female, Fibronectin, Humans, Immunofluorescence, MDA-MB-231 cells, Medical prognosis, Mesenchyme, Metastasis, Mice, Mice, Inbred BALB C, Neoplasm Invasiveness, NF-κB protein, Phosphorylation - drug effects, Proteins, Regulation, Response rates, Resveratrol, Resveratrol - pharmacology, Signal Transduction - drug effects, Smad2 protein, Smad3 protein, Synergistic effect, Transforming Growth Factor beta1 - pharmacology, Transforming growth factor-b1, Triple Negative Breast Neoplasms - pathology, Vimentin, Weight loss, Weight reduction, Xenograft Model Antitumor Assays, Xenografts, Xenotransplantation